-
N286797-25mgNHI-2 is a potent inhibitor of LDH-A. NHI-2 is an efficient anti-glycolytic agent. NHI-2 has the potential for the research of cancer disease.
-
N286797-50mgNHI-2 is a potent inhibitor of LDH-A. NHI-2 is an efficient anti-glycolytic agent. NHI-2 has the potential for the research of cancer disease.
-
N286797-5mgNHI-2 is a potent inhibitor of LDH-A. NHI-2 is an efficient anti-glycolytic agent. NHI-2 has the potential for the research of cancer disease.
-
Ab177891-100μgNI-0701 (anti-CCL5) is a antibody tageting CCL5.
-
Ab177891-10mgNI-0701 (anti-CCL5) is a antibody tageting CCL5.
-
Ab177891-1mgNI-0701 (anti-CCL5) is a antibody tageting CCL5.
-
Ab177891-5mgNI-0701 (anti-CCL5) is a antibody tageting CCL5.
-
cl155900-200μgProduct Description:The NIH/3T3 whole cell was prepared using a standard whole cell lysate protocol. The concentration was determined using the BCA assay process.NIH/3T3 cells are established from a NIH Swiss mouse embryo. These cells are highly
-
Ab177882-100μgNimacimab (anti-CNR1) is a negative-allosteric modulating monoclonal antibody targeting CB1 receptor. Nimacimab can be used for research of metabolic diseases.
-
Ab177882-10mgNimacimab (anti-CNR1) is a negative-allosteric modulating monoclonal antibody targeting CB1 receptor. Nimacimab can be used for research of metabolic diseases.
-
Ab177882-1mgNimacimab (anti-CNR1) is a negative-allosteric modulating monoclonal antibody targeting CB1 receptor. Nimacimab can be used for research of metabolic diseases.
-
Ab177882-5mgNimacimab (anti-CNR1) is a negative-allosteric modulating monoclonal antibody targeting CB1 receptor. Nimacimab can be used for research of metabolic diseases.